NCT03237728已完成1 期
Randomized, Double-blind Placebo-controlled Clinical Study to Assess Safety, Tolerance, Pharmacokinetics, Pharmacodynamic of Multiple-dose Kukoamine B Mesilate in Sepsis Patients
Tianjin Chasesun Pharmaceutical Co., LTD1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2017年7月28日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- Incidence of adverse events
研究概览
简要总结
Phase I study of multiple-dose Kukoamine B Mesilate in Sepsis Patients
详细描述
To Assess Safety, Tolerance, Pharmacokinetics, Pharmacodynamic of multiple-dose Kukoamine B Mesilate in Sepsis Patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The age of ≥ 18 years of age and ≤ 70 years of age, gender is not limited;
- •Confirmed or suspected bacterial infection (refer to Appendix 5);
- •Infection-related organ failure does not exceed 24 hours; organ failure is defined as circulation, (SOFA) ≥ 3 points in at least one organ or system of the respiratory, kidney, liver, coagulation and central nervous system;
- •The time interval between the selection of the test drug and the test drug is not more than 8 hours;
- •Infertility test for women of childbearing age;
- •Childbearing age within six months without child care plan and agreed to take effective measures during the study of contraception;
- •Patients or legal representatives signed informed consent.
排除标准
- •Pregnant or lactating women, or unable to take effective measures of contraception;
- •Patients are expected to live less than 28 days due to basic diseases, such as poor control of malignant tumor, cardiac arrest in 30 days, and end-stage lung disease.
- •The patient has the following chronic organ dysfunction or immunosuppression (based on the chronic health scoring assessment of the APACHE II score) : a) heart: New York heart association cardiac function IV; B) breathing: chronic obstructive, obstructive, or vascular lung disease can lead to severe restrictions on activities, i.e. the inability to go upstairs or to do housework; Or clear chronic hypoxia, CO2 retention, secondary real erythrocyte, severe pulmonary hypertension (> 40 mmHg) or respiratory muscle dependence; C) kidneys: receiving long-term dialysis; D) liver: liver cirrhosis confirmed by biopsy and clear portal hypertension; The upper digestive tract hemorrhage caused by portal hypertension; Or previous liver failure/hepatic encephalopathy/hepatic coma; E) of immune function: accept the treatment of impact resistance to infection, such as immune suppression therapy, chemotherapy, radiation therapy, or for a long time the recent use of high doses of hormones), or sickness impact resistance to infection, such as leukemia, lymphoma and AIDS);
- •Solid organ or bone marrow transplantation;
- •Plant survival status;
- •The following conditions occurred within 4 weeks prior to infection: a) acute pulmonary embolism; B) transfusion response; C) acute coronary syndrome;
- •Confirmed or highly suspected of acute infectious diseases such as viral hepatitis activity and active tuberculosis;
- •Patients with sinus bradycardia (less than 60 per minute);
- •Severe anemia (hemoglobin < 7.0 g/dL);
- •Uncontrolled bleeding in the past 24 hours;
- •Large area burns or chemical burns (III degree burns area > 30% BSA);
- •The average arterial pressure was < 65 mmHg after adequate liquid resuscitation and vasoactive drug therapy.
- •Acute myeloid hematopoiesis was characterized by a lack of severe granulocytes (ANC < 500 / mm3), or severe thrombocytopenia (< 20,000 / mm3);
- •Allergic to the active ingredient or its auxiliary materials;
- •The medication patients are using may severely affect the metabolism of the drug;
- •Patients and (or) legal representatives have signed an unresuscitation (DNR), or decided to withdraw life support (withdraw) or restrict life support for the intensity (of the patient) and sign the informed consent form;
- •Participated in clinical intervention test in 3 months;
- •The subject is a researcher or his immediate family member, or may have improper informed consent;
- •The attending physician considers it inappropriate for the patient to participate in this test.
研究组 & 干预措施
0.06mg/kg,KB and Placebo
Experimental
Group A:0.06mg/kg,Q8h,Day1-Day7
干预措施: 0.06mg/kg,KB (Drug)
0.06mg/kg,KB and Placebo
Experimental
Group A:0.06mg/kg,Q8h,Day1-Day7
干预措施: Placebos (Drug)
0.12mg/kg,KB
Experimental
Group B:0.12mg/kg,Q8h,Day1-Day7
干预措施: 0.12mg/kg,KB (Drug)
0.24mg/kg,KB
Experimental
Group C:0.24mg/kg,Q8h,Day1-Day7
干预措施: 0.24mg/,KB (Drug)
Placebos
Experimental
Group D:Placebos,Q8h,Day1-Day7
干预措施: Placebos (Drug)
结局指标
主要结局
Incidence of adverse events
时间窗: Day-1 to Day8
AE, physical examination, monitoring of vital signs, Laboratory examination etc.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaSplenic Marginal Zone LymphomaWaldenström MacroglobulinemiaNCT02049541Kami Maddocks, MD18
已完成
2 期
GINECO-EN102b - BKM120 as Monotherapy in the Treatment of Initial or Recurrent Metastatic Endometrial CancerEndometrial CancerNCT01397877ARCAGY/ GINECO GROUP24
招募中
2 期
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for SarcomasSarcomaMPNSTNF1NCT05253131University of Alabama at Birmingham41
已完成
2 期
Effect of KB003 in Subjects With Asthma Inadequately Controlled by CorticosteroidsModerate-to-Severe AsthmaNCT01603277Humanigen, Inc.160
已完成
1 期
Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023Human Immunodeficiency VirusNCT01348516Kainos Medicine Inc.83